ESC/ERS guidelines: route of administration, half-life, dose ranges, increments and duration of administration of the most commonly used agents for pulmonary vasoreactivity tests
| Drug | Route | Half-life | Dose range# | Increments¶ | Duration+ |
| Epoprostenol | Intravenous | 3 min | 2–12 ng·kg−1·min−1 | 2 ng·kg−1·min−1 | 10 min |
| Adenosine | Intravenous | 5–10 s | 50–350 μg·kg−1·min−1 | 50 μg·kg−1·min−1 | 2 min |
| Nitric oxide | Inhaled | 15–30 s | 10–20 ppm | 5 min§ |
#: initial dose and maximal tolerated dose suggested (maximal dose limited by side-effects such as hypotension, headache, flushing, etc.); ¶: increments of dose by each step; +: duration of administration on each step; §: for nitric oxide, a single step within the dose range is suggested. Reproduced from 1 with permission from the publisher.